Home » Stocks » EDIT

Editas Medicine, Inc. (EDIT)

Stock Price: $34.11 USD -0.23 (-0.67%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $34.51 +0.40 (1.17%) May 7, 7:53 PM
Market Cap 2.31B
Revenue (ttm) 91.51M
Net Income (ttm) -134.98M
Shares Out 65.99M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $34.11
Previous Close $34.34
Change ($) -0.23
Change (%) -0.67%
Day's Open 35.32
Day's Range 34.05 - 36.79
Day's Volume 1,300,626
52-Week Range 23.51 - 99.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.

2 days ago - Zacks Investment Research

Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 days ago - Zacks Investment Research

Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer

3 days ago - GlobeNewsWire

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company's Executi...

3 days ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets were getting crushed.

Other stocks mentioned: RBLX, TEVA, X
3 days ago - 24/7 Wall Street

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboratio...

4 days ago - GlobeNewsWire

Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4 Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis...

1 week ago - GlobeNewsWire

Here is what you should know about investing in these life changing technologies.

Other stocks mentioned: BNTX, CHNA, CNCR, CRSP, CVAC, IBB, MRNA ...
1 week ago - Zacks Investment Research

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday,...

1 week ago - GlobeNewsWire

Broader markets be at all-time highs, but there are still opportunities for the coming months. Here are seven stocks to buy this May.

Other stocks mentioned: CLDR, KWEB, MO, ROKU, SMOG, TME
1 week ago - InvestorPlace

On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.

1 week ago - Zacks Investment Research

A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Other stocks mentioned: CRSP, NTLA
3 weeks ago - InvestorPlace

Investors are trying to figure out which stocks have the best prospects.

Other stocks mentioned: WKHS
3 weeks ago - The Motley Fool

Investors are running for the hills following this analyst take on the biotech's prospects.

3 weeks ago - The Motley Fool

Goldman says Editas' clinical data may underwhelm. We don't agree.

Other stocks mentioned: GS
3 weeks ago - InvestorPlace

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ACAD, ALXN, AZN, BIIB, BNTX, CRSP ...
4 weeks ago - Investors Business Daily

Start this year's spring cleaning by asking yourself the right questions.

Other stocks mentioned: DIS, ETSY, FIVE, GME, SFIX, TRIP, W
4 weeks ago - The Motley Fool

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Other stocks mentioned: BEAM, CLLS, CRSP, NTLA
1 month ago - InvestorPlace

Our indicative theme of Gene Editing stocks is down by about 19% year-to-date, compared to the S&P 500 which is up by about 6% over the same period. With the economic recovery expected to gather pace, o...

1 month ago - Forbes

All three of these stocks appear to be great comeback candidates.

Other stocks mentioned: BEPC, TRUP
1 month ago - The Motley Fool

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...

Other stocks mentioned: BEAM, BLUE, CRSP, NTLA
1 month ago - InvestorPlace

A strong overall stock market performance is lifting the biotech stock.

1 month ago - The Motley Fool

Our indicative theme of Gene Editing stocks is down by about 24% year-to-date, compared to the S&P 500 which has remained almost flat over the same period. The recent sell-off comes on the back of risin...

Other stocks mentioned: NTLA
1 month ago - Forbes

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A pair of chief executives and an executive board chair were among the insiders making purc...

Other stocks mentioned: XOM
2 months ago - Benzinga

Short-term issues shouldn't affect long-term investors.

2 months ago - The Motley Fool

The stock was pulled down by the undertow of the broader market sell-off.

2 months ago - The Motley Fool

With the trading day about halfway over, the broad markets came roaring back to start out the week.

Other stocks mentioned: BCRX, GRPN, RUN, TWTR
2 months ago - 24/7 Wall Street

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Other stocks mentioned: ABNB
2 months ago - 24/7 Wall Street

ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.

Other stocks mentioned: AMZN, ARKK, CGEN
2 months ago - GuruFocus

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

2 months ago - Zacks Investment Research

After a huge run-up in valuation, investors are a little spooked.

2 months ago - The Motley Fool

Turnover at the top of a company can be troubling. But it can sometimes be a good thing.

2 months ago - The Motley Fool

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, F...

2 months ago - GlobeNewsWire

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

In a field that's becoming more crowded, what will set Editas apart?

2 months ago - The Motley Fool

On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.

2 months ago - Zacks Investment Research

Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.

2 months ago - Zacks Investment Research

As more young investors take up day trading, I have a recipe for long-term wealth creation

Other stocks mentioned: ARKK, GME, NVDA, TSLA
2 months ago - Zacks Investment Research

As more young investors take up day trading, I have an important recipe for long-term wealth creation.

Other stocks mentioned: ARKK, GME, NVDA, TSLA
2 months ago - Zacks Investment Research

Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech.

2 months ago - The Motley Fool

Which of these two hot gene therapy stocks is the better buy?

Other stocks mentioned: CRSP
3 months ago - The Motley Fool

In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.

3 months ago - Zacks Investment Research

Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Our indicati...

Other stocks mentioned: NTLA
3 months ago - Forbes

Could this maverick biotech discover the cure for several debilitating rare diseases?

3 months ago - The Motley Fool

In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.

3 months ago - Zacks Investment Research

Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to issue 3.5 ...

3 months ago - Forbes

It's a big bet but not a big gamble.

Other stocks mentioned: GH, ISRG, TDOC, VRTX, XBI
3 months ago - The Motley Fool

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Other stocks mentioned: CRSP, JNJ, SPY, VRTX, VTI
3 months ago - The Motley Fool

Sana Biotechnology Seeks $150 Million U.S. IPO

Other stocks mentioned: BMY, CRSP, GILD, JNJ, NVO, NVS
3 months ago - Seeking Alpha

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is... [Read more...]

Industry
Biotechnology
IPO Date
Feb 3, 2016
CEO
Cynthia Collins
Employees
235
Stock Exchange
NASDAQ
Ticker Symbol
EDIT
Full Company Profile

Financial Performance

In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 47.67, which is an increase of 39.75% from the latest price.

Price Target
$47.67
(39.75% upside)
Analyst Consensus: Buy